Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis

By Philip J. Barter, H. Brewer, M. Chapman, C. Hennekens, Daniel J. Rader, Alan R. Tall. Arteriosclerosis, Thrombosis and Vascular Biology, 2003

878 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis (2006, background): “3) (Asztalos and Schaefer, 2003; Barter et al., 2003b).”
Cholesterol efflux and atheroprotection: Advancing the concept of reverse cholesterol transport (2012, result): “Similar to LCAT animal models, variable results on atherosclerosis have been obtained in mice most likely because of the need to overexpress CETP in this animal model naturally lacking CETP (90,91).”
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel (2020, background): “The composition of IDL-derived LDL is modulated both by CETP-mediated transfer of cholesteryl esters (CE) from high-density lipoprotein (HDL) and by CETP-mediated transfer of TG from VLDL and their remnants.(102,106) (B) In individuals with low plasma TG, LDL-I and -II predominate.”